PASCAL BIOSCIENCES PLANS NEW DIRECTION TO INCLUDE CONTRACT RESEARCH

 

VANCOUVER, BRITISH COLUMBIA, June 14, 2022. Pascal Biosciences Inc. (“Pascal” or “the Company”) (TSXV:PAS) (OTC:PSCBF) (FSE: 6PB-FF) is announcing a renewed and expanded emphasis on the consulting and contract research component of the business. Pascal has previously had success by providing resources to other biotech companies. In particular, the Company worked with SoRSE Technology last year, bringing over $600,000 into the company. Pascal scientists have, combined, over 80 years of experience in biotechnology projects and have been involved in the discovery, preclinical, and clinical development of drugs approved by the FDA. Our intent is to leverage this expertise to provide consulting and research services to customers with projects primarily  in the post-discovery to Phase I period of development.

 

“Drug development has long timelines and, unless new drug candidates are forthcoming, preclinical teams tend to become redundant once a drug enters clinical studies.”  stated CEO Dr. Brian Bapty. “By providing virtual preclinical services, Pascal can provide the direction, experience, and facilities to efficiently support multiple preclinical programs.” As with the SoRSE contract, Pascal will provide shared expertise and infrastructure so Biotech clients benefit from economies of scale while limiting fixed costs.

 

Pascal is in process of updating the website to reflect these changes. Pascal will continue development of internal programs notably, for Acute Lymphoblastic Leukemia which is funded by an NIH Grant, and glioblastoma which will be supported by funds from operations.

 

 

ABOUT PASCAL BIOSCIENCES INC.

 

Pascal is a biotechnology company advancing innovative therapies for serious diseases. In addition to a targeted therapy for Acute Lymphoblastic Leukemia, Pascal is developing cannabinoid-based treatments for cancer. These compounds include PAS-403, which is advancing towards clinical trials for the treatment of glioblastoma, and PAS-393, an immuno-stimulatory cannabinoid to be used in combination with checkpoint inhibitor therapy to treat multiple cancers. The PAS-393 program was previously developed in collaboration with SoRSE Technology. PAS-393 also shows promise for treating Covid-19, and Pascal holds a patent for the use of cannabinoids in treatment of Covid-19.

 

To learn more, visit: https://www.pascalbiosciences.com/.

 

Company Contact:

Dr. Brian Bapty, CEO
Dr. Patrick W. Gray, Chairman

invest@pascalbiosciences.com

Tel: 206-221-7041

 

Forward-Looking Statements

DISCLAIMER
Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.

 

“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release”